Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its oxycodone, naloxone product, LY 021702. The drug is indicated for use in adults requiring opioid analgesics to manage severe pain, including both cancer-related and non-cancer pain.
Oxycodone is a potent opioid analgesic known for its effective pain management but is also associated with a risk of addiction, abuse, and gastrointestinal adverse reactions. LY 021702 is the first oxycodone, naloxone sustained-release product developed by a Chinese company. It is designed to treat moderate to severe chronic pain that cannot be effectively managed with non-opioid analgesics, offering a 12-hour duration of pain relief. Additionally, LY 021702 is formulated to help prevent opioid abuse and mitigate gastrointestinal adverse reactions such as constipation commonly associated with opioid use.- Flcube.com
